1. Zierhut, M., Mizuki, N., Ohno, S., et al. Immunology and functional genomics of Behcet's disease. Cellular and Molecular Life Sciences CMLS, 2003 (60), 1903-1922.
2. Taheri, S., Borlu, M., Evereklioglu, C., Ozdemir, S. Y. & Ozkul, Y. mRNA expression level of interleukin genes in the determining phases of Behçet’s Disease. Annals of dermatology 2015 (27), 291–297.
3. Kulaber, A., Tugal-Tutkun, I., Yentür, S. P., et al. Pro-inflammatory cellular immune response in Behçet’s disease. Rheumatology International, 2007 (27), 1113-1118.
4. Gurler, A., Boyvat, A. & Tursen, U. Clinical manifestations of Behçet’s Disease: an analysis of 2147 patients. Yonsei medical journal 1997 (38), 423–427.
5. Nakamura, K., Tsunemi, Y., Kaneko, F. & Alpsoy, E. Mucocutaneous manifestations of Behçet’s Disease. Frontiers in Medicine 2021 (7), 613432.
6. Tong, B., Liu, X., Xiao, J. & Su, G. Immunopathogenesis of Behcet’s disease. Frontiers in immunology 2019 (10), 665.
7. Balkan, E., Bilen, H., Eyerci, N., et al. Cytokine, C-reactive protein, and heat shock protein mRNA expression levels in patients with active Behçet’s uveitis. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 2018 (24), 1511.
8. Karadağ, R., Koca, C., Totan, Y., et al. Comparison of serum levels of IL-6, IL-8, TNF-α, C reactive protein and heat shock protein 70 in patients with active or inactive Behçet’s disease. Turkish Journal of Medical Sciences, 2010 (40) (1), 57-62.
9. Bardak, Y. & Aridogan, B. C. The demonstration of serum interleukin 6–8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet’s Disease with ocular involvement. Ocular immunology and
inflammation 2004 (12), 53–58.
10. Akdeniz, N., Esrefoglu, M., Keles, M., Karakuzu, A. & Atasoy, M. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet’s disease. ANNALS-ACADEMY OF MEDICINE SINGAPORE 2004 (33), 596–599.
11. Wechsler, F. B., and F. Davatchi. "Criteria for diagnosis of Behcet's disease." The Lancet 335.8697 1990: 1078-1080.
12. Müftüoǧlu, A., Yazici, H., Yurdakul, S., et al. Behçet's Disease: Relation of Serum C‐reactive Protein and Erythrocyte Sedimentation Rates to Disease Activity. International journal of dermatology, 1986-25(4), 235-239.
13. Fernandez-Botran, R. Soluble cytokine receptors: their role in immunoregulation. The FASEB journal 1991 (5), 2567–2574.
14. Kroemer, G., Andreu, J. L., Gonzalo, J. A., Gutierrez-Ramos, J. C. & Martınez-A, C. Interleukin-2, autotolerance, and autoimmunity. Advances in immunology 1991 (50), 147–235.
15. Kharroubi, W., Ahmed, S. H., Nury, T., et al. Mitochondrial dysfunction, oxidative stress and apoptotic induction in microglial BV-2 cells treated with sodium arsenate. Journal of Environmental Sciences, 2017 (51), 44-51.
16. Beutler, B. A. The role of tumor necrosis factor in health and disease. The journal of rheumatology. Supplement 57, 16–21 (1999).
17. Opal, S. M. & DePalo, V. A. Anti-inflammatory cytokines. Chest 2000 (117), 1162–1172.
18. Wu, Z., Zheng, W., Xu, J., et al. IL10 polymorphisms associated with Behçet’s disease in Chinese Han. Human immunology, 2014-75(3), 271-276.
19. Khaib Dit Naib, O., Aribi, M., Idder, A., et al. Association analysis of IL10, TNF-α, and IL23R-IL12RB2 SNPs with Behçet’s disease risk in Western Algeria. Frontiers in immunology, 2013 (4), 342.
20. Talaat, R. M., Sibaii, H., Bassyouni, I. H., & El-Wakkad, A. IL-17, IL-10, IL-6, and IFN-γ in Egyptian Behçet’s disease: correlation with clinical manifestations. European Cytokine Network, 2019 (30), 15-22.
21. Raziuddin, S., Al-Dalaan, A., Bahabri, S., Siraj, A. & Al-Sedairy, S. Divergent cytokine production profile in BD. Altered Th1/Th2 cell cytokine pattern. The Journal of rheumatology 1998 (25), 329–333.
22. Hamzaoui, K., Hamzaoui, A., Guemira, F., et al. Cytokine profile in Behçet's disease patients. Scandinavian journal of rheumatology, 2002-31(4), 205-210.
23. Ben Ahmed, M., Houman, H., Miled, M., Dellagi, K. & Louzir, H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet’s Disease. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 2004 (50), 2291–2295.
24. Aridogan, B. C., Yildirim, M., Baysal, V., et al. Serum levels of IL‐4, IL‐10, IL‐12, IL‐13 and IFN‐gamma in Behçet's disease. The Journal of dermatology, 2003-30(8), 602-607.
25. Cingu, A. K., Turkcu, F. M., Aktas, S., Sahin, A. & Ayyildiz, O. Serum IL-4, IL-12, IL-13, IL-27, and IL-33 levels in active and inactive ocular Behcet’s disease. International Ophthalmology 2020 (40), 3441–3451.
26. Novak, T., Hamedi, M., Bergmeier, L. A., Fortune, F. & Hagi-Pavli, E. Saliva and Serum Cytokine Profiles during Oral Ulceration in Behçet’s Disease. Frontiers in immunology 2021- 12.
27. Van der Houwen, T., van Hagen, P. & van Laar, J. Immunopathogenesis of Behçet’s Disease and treatment modalities in Seminars in Arthritis and Rheumatism 2022 (52) 1956.
28. Coskun, M., Bacanli, A., Sallakci, N., et al. Specific interleukin‐1 gene polymorphisms in Turkish patients with Behçet's disease. Experimental dermatology, 2005-14(2), 124-129.
29. Evereklioglu, C., Er, H., Türköz, Y. & Çekmen, M. Serum levels of TNFα, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s Disease. Mediators of inflammation 2002 (11), 87–93.
30. Takeuchi, M., Kastner, D. L. & Remmers, E. F. The immunogenetics of Behçet’s Disease: A comprehensive review. Journal of autoimmunity 2015 (64), 137–148.
31. Xavier, J. M., Shahram, F., Davatchi, F., et al. Association study of IL10 and IL23R–IL12RB2 in Iranian patients with Behcet's disease. Arthritis & Rheumatism, 2012-64(8), 2761-2772.
32. Akkurt, Z. M., Bozkurt, M., Uçmak, D., et al. Serum cytokine levels in Behçet's disease. Journal of clinical laboratory analysis, 2015-29(4), 317-320.
33. Balta, I., Balta, S., Koryurek, O. M., et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. Journal of the American Academy of Dermatology, 2014-70(2), 291-296.
34. Bekpinar, S., Kiliç, N., Ünlüçerçi, Y., et al. Evaluation of nitrosative and oxidative stress in Behcet disease. Journal of the European Academy of Dermatology and Venereology, 2005-19(2), 167-171.
35. Hasan, M., Bergmeier, L. A., Petrushkin, H., et al. Gamma delta (γδ) T cells and their involvement in Behçet’s Disease. Journal of immunology research 2015 (2015).
36. Hou, C.-c. & Guan, J.-l. Risk factors of disease activity in patients with Behçet’s syndrome. Clinical Rheumatology 2021 (40), 1465–1471.
37. Parsaei, A., Moradi, S., Masoumi, M., et al. Predictive value of erythrocyte sedimentation rate and C-reactive protein in Behcet's disease activity and manifestations: a cross-sectional study. BMC rheumatology, 2022-6(1), 1-9.
38. Becatti, M., Emmi, G., Bettiol, A.., et al. Behçet’s syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects. Clinical & Experimental Immunology, 2019-195(3), 322-333.